A panel of the authors on our Lancet Haematology-Lancet Regional Health Western Pacific Series on mature T-cell and natural killer-cell lymphomas

Lan-Lan Smith, Cheryl Lai, and Daniela Marín discuss the EHA, ICML, and ISTH conferences

Paolo Strati on off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma

A panel of the authors on our Adverse Events Series on adverse event reporting in haematological malignancies

Michael Northend on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma

Joanne Verweij and Romy Pothof on fetal and neonatal alloimmune thrombocytopenia

Helene Schoemans, Elke Stienissen, and Kathy Goris on a consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe

Dawn Swan on air pollution and venous thromboembolism

Leslie Skeith on low-dose aspirin for postpartum venous thromboembolism prophylaxis

Neema Mayor and Caitlin Farrow on impact of patient ethnicity on haematopoeietic cell transplantation outcome in the United Kingdom

Lancet Haematology 10 year anniversary - meet the editors

Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome

Kim Linton on follicular lymphoma

Judy Truong on ferritin reference levels and iron deficiency

Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML

Banu Aygun on sickle cell anaemia

Sabine Braat and Katherine Fielding on haemoglobin thresholds to define anaemia

Elisabeth Schorb on the MARTA phase 2 trial

Stephan Ehl on paediatric autoimmune lymphoproliferative immunodeficiencies

Dr Sarah O'Brien on the PREVAPIX-ALL trial